Mostrar el registro sencillo del ítem

dc.contributor.authorGarcia-Vidal, Carolina
dc.contributor.authorIglesias-Caballero, Maria 
dc.contributor.authorPuerta-Alcalde, Pedro
dc.contributor.authorMas-Lloret, Vicente 
dc.contributor.authorCuesta-Chasco, Genoveva
dc.contributor.authorGarcia-Pouton, Nicole
dc.contributor.authorVarona Fernandez, Sarai 
dc.contributor.authorPozo Sanchez, Francisco 
dc.contributor.authorVazquez-Moron, Sonia 
dc.contributor.authorMarcos, Maria Angeles
dc.contributor.authorSoriano, Alex
dc.contributor.authorCasas Flecha, Inmaculada 
dc.contributor.authorHEMATOCOVID19-Researchers Group
dc.date.accessioned2022-05-24T08:25:52Z
dc.date.available2022-05-24T08:25:52Z
dc.date.issued2022-03-03
dc.identifier.citationFront Microbiol. 2022 Mar 3;13:826883.es_ES
dc.identifier.issn1664-302Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14475
dc.description.abstractWe documented a hematologic patient with prolonged SARS-CoV-2 viral replication in whom emergence of viral mutations was documented after the consecutive use of antivirals and convalescent plasma. The virus detected in the last of 12 clinical samples (day 237) had accumulated 22 changes in amino acids and 29 in nucleotides. Some of these changes, such as the E484Q, were mutations of concern as defined by WHO. This finding represents an enormous epidemiological threat and poses a major clinical challenge. Combined antiviral strategies, as well as specific strategies related to the diagnostic approach of prolonged infections for this specific population, may be needed.es_ES
dc.description.sponsorshipThis work has been financed by funds for research ad hoc COVID-19 from patronage provided by citizens and organizations to Hospital Clínic de Barcelona-Fundació Clínic per a la Recerca Biomèdica. This work received support from FONDO-COVID19 (ISCIII Grant number: COV20-00679), Instituto de Salud Carlos III (PI21/01640) and by European Region (ERDF, “A way to make Europe”). PP-A [JR20/00012 and PI21/00498], NG-P [FI19/00133], have also received research grants from the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III. The funders had neither a specific role in study design or collection of data, nor in writing of the paper or decision to submit.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCOVID-19es_ES
dc.subjectAntiviralses_ES
dc.subjectHematologyes_ES
dc.subjectImmunosuppressiones_ES
dc.subjectMutationses_ES
dc.subjectPersistencees_ES
dc.subjectRemdesivires_ES
dc.titleEmergence of Progressive Mutations in SARS-CoV-2 From a Hematologic Patient With Prolonged Viral Replicationes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID35308337es_ES
dc.format.volume13es_ES
dc.format.page826883es_ES
dc.identifier.doi10.3389/fmicb.2022.826883es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderHospital Clínic de Barcelonaes_ES
dc.contributor.funderMinisterio de Sanidad (España) es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fmicb.2022.826883es_ES
dc.identifier.journalFrontiers in Microbiologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20-00679es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/JR20/00012es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI21/00498es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/FI19/00133es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI21/01640es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional